These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36915864)

  • 1. The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste.
    Donners AAMT; van der Zwet K; Rademaker CMA; Egberts TCG; Schutgens REG; Fischer K
    Res Pract Thromb Haemost; 2023 Feb; 7(2):100074. PubMed ID: 36915864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A.
    Donners A; van der Zwet K; Egberts ACG; Fijnvandraat K; Mathôt R; Kruis I; Cnossen MH; Schutgens R; Urbanus RT; Fischer K
    BMJ Open; 2023 Jun; 13(6):e072363. PubMed ID: 37369395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis.
    Pipe SW; Trzaskoma B; Minhas M; Lehle M; Ko RH; Gao L; Mahlangu J; Kempton CL; Kessler CM; Kruse-Jarres R
    Res Pract Thromb Haemost; 2023 Feb; 7(2):100077. PubMed ID: 36908770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.
    Batt K; Schultz BG; Caicedo J; Hollenbeak CS; Agrawal N; Chatterjee S; Bullano M
    Curr Med Res Opin; 2022 Oct; 38(10):1685-1693. PubMed ID: 35880468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste.
    D'Albini L; Dorholt M; Gallucci L
    J Manag Care Spec Pharm; 2023 Jan; 29(1):47-57. PubMed ID: 36580124
    [No Abstract]   [Full Text] [Related]  

  • 7. Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A.
    Schmitt C; Mancuso ME; Chang T; Podolak-Dawidziak M; Petry C; Sidonio R; Yoneyama K; Key NS; Niggli M; Lehle M; Peyvandi F; Oldenburg J
    Haemophilia; 2023 Jan; 29(1):90-99. PubMed ID: 36271487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors.
    Cafuir L; Estrin A; Chen E; Hinds D; Prince P; Thorburn J; Mead H; Kempton CL
    J Med Econ; 2022; 25(1):984-992. PubMed ID: 35848992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US.
    Lewandowska M; Randall N; Bakeer N; Maahs J; Sagar J; Greist A; Shapiro AD
    Haemophilia; 2021 Jan; 27(1):90-99. PubMed ID: 33245841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen.
    Bukkems LH; Fischer K; Kremer-Hovinga I; Donners AAM; Fijnvandraat K; Schutgens REG; Cnossen MH; Mathôt RAA
    Thromb Haemost; 2022 Feb; 122(2):208-215. PubMed ID: 33946119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review.
    Donners AAMT; Rademaker CMA; Bevers LAH; Huitema ADR; Schutgens REG; Egberts TCG; Fischer K
    Clin Pharmacokinet; 2021 Nov; 60(11):1395-1406. PubMed ID: 34389928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China.
    Liu G; Huang K; Li G; Zhen Y; Li Z; Chen Z; Wu R
    Front Pediatr; 2022; 10():992267. PubMed ID: 36340724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study.
    Yu JK; Iorio A; Chelle P; Edginton AN
    Haemophilia; 2021 May; 27(3):358-365. PubMed ID: 33650745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience.
    Rener K; Anžej Doma S; Fink M; Podgornik H; Preložnik Zupan I
    Hematol Rep; 2023 Nov; 15(4):597-607. PubMed ID: 37987318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5).
    Yang R; Wang S; Wang X; Sun J; Chuansumrit A; Zhou J; Schmitt C; Hsu W; Xu J; Li L; Chang T; Zhao X
    Res Pract Thromb Haemost; 2022 Feb; 6(2):e12670. PubMed ID: 35284778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single-center experience in Bangladesh.
    Tory SS; Ghosh S; Nazneen H; Farhad N; Islam S; Hasan MJ; Biswas AR
    EJHaem; 2024 Feb; 5(1):39-46. PubMed ID: 38406515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
    Reyes A; Révil C; Niggli M; Chebon S; Schlagmüller S; Flacke JP; Zortel M; Paz-Priel I; Asikanius E; Hampton R; Mahajan A; Schmidt E; Edwards SC
    Curr Med Res Opin; 2019 Dec; 35(12):2079-2087. PubMed ID: 31355677
    [No Abstract]   [Full Text] [Related]  

  • 18. Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors.
    Castaman G; Peyvandi F; Kremer Hovinga JA; Schutgens REG; Robson S; Moreno K; Jiménez-Yuste V
    TH Open; 2024 Jan; 8(1):e42-e54. PubMed ID: 38222041
    [No Abstract]   [Full Text] [Related]  

  • 19. Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report.
    Warren BB; Chan A; Manco-Johnson M; Branchford BR; Buckner TW; Moyer G; Gibson E; Thornhill D; Wang M; Ng CJ
    Res Pract Thromb Haemost; 2021 Jul; 5(5):e12571. PubMed ID: 34377887
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.